We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Clare
Jordison
clare.jordison@ncl.ac.uk
Christine
Dyer
christine.dyer@ncl.ac.uk
Miss
Laura
Brown
laura.brown8@ncl.ac.uk
Dr
Yi Shiau
Ng
yi.ng@newcastle.ac.uk
Douglas
Jerry
douglas.jerry@ncl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Diseases of myoneural junction and muscleSystemic atrophies primarily affecting the central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Cerebellar ataxia develops as the result of damage to the cerebellum, a part of the brain that controls co-ordination and the ability to move.
Patients with cerebellar ataxia often experience problems with poor balance, leading to falls and injuries, as well as speech and swallowing difficulties.
Progressive cerebellar ataxia affects two-thirds of adult patients with mitochondrial disease. Patients suffer from repeated falls, impaired quality of life and increased dependency on their family and wider community when symptoms are severe.
This project aims to investigate the severity and progression of cerebellar ataxia in adult patients with mitochondrial disease.
The assessment of cerebellar ataxia will be performed using three different approaches: assessment of signs and symptoms along with questionnaires, analysis of posture and walking and the use of transcranial magnetic stimulation (TMS).
These tests will be performed on participants with mitochondrial disease and also on control participants at baseline. The tests will then be repeated on the participants with mitochondrial disease after 12 months to detect any change in cerebellar ataxia symptoms over this period.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
1. Aged < 16 or > 70 years. 2. Lacking cognitive capacity to provide informed consent and participate in study assessments. 3. Uncontrolled medical problems such as epilepsy, which in the opinion of the investigator would preclude participation in the study. 4. Implanted medical devices such as cochlear implants, pacemaker, LINQ device and vagal nerve stimulator. 5. Inability to walk independently for a short distance (e.g. 20m). 6. Mobility that is significantly impaired by other co-morbidities, which affect gait. 7. Pregnancy 8. Language barriers preventing reading and comprehension in English. 9. Participation in an interventional clinical study that in the opinion of the recruiting investigator may affect performance in the study assessments.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Christine
Dyer
christine.dyer@ncl.ac.uk
Dr
Yi Shiau
Ng
yi.ng@newcastle.ac.uk
Douglas
Jerry
douglas.jerry@ncl.ac.uk
Miss
Laura
Brown
laura.brown8@ncl.ac.uk
Clare
Jordison
clare.jordison@ncl.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST and funded by ACADEMY OF MEDICAL SCIENCES .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 43173
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
